HIGH POINT, NC, March 18, 2021 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on developing orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study examining the effects of TTP399 on ketone formation during a period of insulin withdrawal in people with type 1 diabetes. The phase 1 study tests the hypothesis that treatment with vTvs TTP399, a liver-selective glucokinase activator, does not lead to increased production of ketones, a precursor to ketoacidosis that is hospitalized in patients with type 1 diabetes can lead.
Despite advances in insulin therapy and monitoring technologies, many patients with type 1 diabetes still fail to achieve acceptable glycemic control. Poor blood sugar control has led to a worldwide surge in hospitalizations for people with type 1 diabetes caused by hypoglycemia or diabetic ketoacidosis. TTP399 previously demonstrated improvement in blood sugar control in a three-month phase 2 study in patients with type 1 diabetes without an increased incidence of diabetic ketoacidosis or hypoglycemia.
“Developing a drug that does not increase the risk of diabetic ketoacidosis, or even better has the potential to reduce that risk, while improving glycemic control and reducing the risk of hypoglycemia would be beneficial for those with type 1 diabetes “said Steve Holcombe, CEO of vTv Therapeutics. “This would be a significant improvement over insulin administration alone.”
The company is advancing the development of TTP399 in type 1 diabetes and is well on its way to initiating the first key study later this year.
About diabetic ketoacidosis
Diabetic ketoacidosis is a serious condition that occurs when the body produces high amounts of blood acids called ketones. It is most common in people with type 1 diabetes and is reported to be the cause of 14% of all hospitalizations for these patients and 16% of all diabetes-related deaths.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs to treat type 1 diabetes and inflammatory diseases, including psoriasis. VTv’s development partners are pursuing additional indications for type 2 diabetes, chronic obstructive pulmonary disease (COPD), kidney disease and primary mitochondrial myopathy. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential “,” Prediction “,” Project “,” Should “,” Goal “,” Will “,” Would “and their respective negative or other different or comparable terminology. All statements other than statements of historical facts contained in this press release, including statements about the timing of our clinical trials, our strategy, future operations, future financial condition, future revenues, projected costs, prospects, plans, management goals and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that could cause our actual results, performance, or accomplishments to differ materially from future results, performance, or accomplishments that are expressed or implied in the forward-looking statements. Important factors that could cause our results to differ from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this publication and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this publication. Unless required by law, we assume no obligation to update or publicly review any forward-looking statements based on new information in the future or events or otherwise after the date of this publication. We assume that later events and developments will cause our views to change. Our forward-looking statements do not reflect the potential effects of any future acquisitions, mergers, disposals, joint ventures or investments that we may make. We qualify all of our forward-looking statements by these cautionary statements.
contacts
Investors:
Corey Davis
LifeSci consultant
CDavis@LifeSciAdvisors.com
or
Media:
PR@vtvtherapeutics.com
